Phaseline

Targets › AGT

AGT (Angiotensinogen): drug programs, companies and trials

3 programs from 2 companies in 3 trials: 1 Phase 2, 1 Phase 1, 1 Phase 3; Cardiovascular; next expected readout Apr 2028.

Essential component of the renin-angiotensin system (RAS), a potent regulator of blood pressure, body fluid and electrolyte homeostasis..; FUNCTION: [Angiotensin-2]: Acts directly on vascular smooth muscle as a potent vasoconstrictor, affects cardiac contractility and heart rate through its action on the sympathetic nervous system, and alters renal sodium and water absorption through its ability to stimulate the…. (UniProt, P01019)

Open in Phaseline: the race on AGT, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Alnylam PharmaceuticalsZilebesiran
Small interfering RNA (siRNA) targeting angiotensinogen (AGT) mRNA
AGTPhase 3High Risk Cardiovascular DiseaseSep 2030
Alnylam PharmaceuticalsALN-AGT01 RVR
RNA interference therapeutic targeting AGT; reduces angiotensinogen production
AGTPhase 2HypertensionApr 2028
CRISPR TherapeuticsCTX340
CRISPR-Cas9 therapy targeting angiotensinogen (AGT) gene disruption in liver
AGTPhase 1HypertensionJul 2028

Conditions

Hypertension (2) High Risk Cardiovascular Disease (1)

Modalities

mixed (1), small molecule (1), other (1)

Companies

Alnylam Pharmaceuticals (2) CRISPR Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.